For Immediate Release
July 1, 2025
CRANFORD, NJ — WBB Securities today announced it had acted as the sole placement agent for a $9 million Series A funding round for FELIQS, a biotechnology company developing first-in-class small molecule therapeutics for rare pediatric retinal diseases.
This investment will accelerate clinical development of FLQ-101, the company’s lead small-molecule candidate for prevention of retinopathy of prematurity (ROP). FLQ-101 is designed to enhance physiological retinal vascularization and protect against inflammation and abnormal neovascularization, which can cause blindness in prematurely born infants.
The round was co-led by a major American pharmaceutical company and Beyond Next Ventures Inc., with additional participation from, Japan Science and Technology Agency and existing investors, Mitsubishi UFJ Capital Co., Ltd., Keio Innovation Initiative, Inc. and FFG Venture Business Partners Co., Ltd.
For further information, go to https://feliqs.reportablenews.com/pr/feliqs-announces-9-million-series-a
About WBB Securities.
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer, a member of FINRA, and a state-registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
